Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Menendez Named To Corzine's New Jersey Senate Seat

This article was originally published in The Pink Sheet Daily

Executive Summary

House Energy & Commerce Committee member Frank Pallone (D-N.J.) is still considering running in the primary for next year's Senatorial election.

New Jersey Governor-Elect Jon Corzine (D) named House Democratic Caucus Chair Robert Menendez (D-N.J.) to his recently vacated Senate seat on Dec. 9.

A special election could be held for Menendez's vacated seat in the 13 district, which borders Merck's Rahway research facility.

House Energy & Commerce Committee member Frank Pallone (D-N.J.), whose sixth district includes Johnson & Johnson's New Brunswick headquarters, had pursued the appointment, as did nearly the rest of the New Jersey Democratic congressional delegation.

With the appointment of Menendez, Pallone announced that he will weigh his options regarding whether to end his campaign for the 2006 Senate election.

Pallone was the only Democratic member of the New Jersey congressional delegation to vote to legalize drug importation through the "Pharmaceutical Market Access Act of 2003."

Menendez gained a significant advantage over Pallone for next year's election though his ascension to the Senate; he has also outpaced Pallone in fundraising thus far, having raised over $4 mil. compared to Pallone's $2 mil.

-John Rancourt

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel